Patents by Inventor Sofiane Ennifar
Sofiane Ennifar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8026109Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: July 14, 2010Date of Patent: September 27, 2011Assignee: Nabi Biopharmaceuticals, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20110217320Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: May 13, 2011Publication date: September 8, 2011Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20110002957Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: July 14, 2010Publication date: January 6, 2011Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7776620Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: July 20, 2007Date of Patent: August 17, 2010Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7754225Abstract: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus epidermidis.Type: GrantFiled: July 20, 2006Date of Patent: July 13, 2010Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ali Fattom, Jawad Sarwar, Zuzana Kossaczka, Kimberly L. Taylor, Sofiane Ennifar
-
Patent number: 7547712Abstract: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.Type: GrantFiled: February 26, 2007Date of Patent: June 16, 2009Assignees: Nabi Biopharmaceuticals, United States of America as Represented by the Secretary, DHHS Office of Technology Transfer, National Institutes of HealthInventors: Sofiane Ennifar, Scott Winston, James Terrill, Steve Fuller
-
Patent number: 7446205Abstract: A high yielding and short process for preparing the 3?-aminomethylnicotine hapten of general formula I permits the isolation of the hapten in very pure quantities. The process can be adapted for the synthesis of a single stereoisomer or mixtures of stereoisomers, such as the stereoisomers trans-Ia and trans-Ib: Compounds of general formula I are useful for the preparation of hapten-carrier conjugates in the treatment of nicotine addiction.Type: GrantFiled: November 16, 2006Date of Patent: November 4, 2008Assignee: Nabi BiopharmaceuticalsInventor: Sofiane Ennifar
-
Publication number: 20080026000Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: July 20, 2007Publication date: January 31, 2008Inventors: Sofiane Ennifar, Ali Fattom, Robert Naso
-
Publication number: 20080019983Abstract: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate of PS1 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus epidermidis.Type: ApplicationFiled: July 20, 2006Publication date: January 24, 2008Applicant: Nabi BiopharmaceuticalsInventors: Ali Fattom, Jawad Sarwar, Zuzana Kossaczka, Kimberly L. Taylor, Sofiane Ennifar
-
Publication number: 20070212364Abstract: The present invention relates methods for reducing the adverse effects of nicotine. This application describes the use of nicotine carrier conjugates in decreasing the toxic effects of nicotine on a fetus.Type: ApplicationFiled: February 26, 2007Publication date: September 13, 2007Inventors: Sofiane Ennifar, Scott Winston, James Terrill, Steve Fuller
-
Patent number: 7247502Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: August 3, 2004Date of Patent: July 24, 2007Assignee: Nabi BiopharmaceuticalsInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20070129551Abstract: A high yielding and short process for preparing the 3?-aminomethylnicotine hapten of general formula I permits the isolation of the hapten in very pure quantities. The process can be adapted for the synthesis of a single stereoisomer or mixtures of stereoisomers, such as the stereoisomers trans-Ia and trans-Ib: Compounds of general formula I are useful for the preparation of hapten-carrier conjugates in the treatment of nicotine addiction.Type: ApplicationFiled: November 16, 2006Publication date: June 7, 2007Inventor: Sofiane Ennifar
-
Publication number: 20060228368Abstract: A method of preventing or treating staphylococcal bacterial infection in an individual is disclosed. A vaccine based on a conjugate the 336 polysaccharide antigen can be used for active protection in individuals who are to be subjected to conditions that place them at immediate risk of developing a bacterial infection, as would be case in the context of a catheterization or a surgical procedure. Alternatively, antibodies raised in response to the antigen can be used to treat or to provide passive protection to individuals. The method can be used in a population of patients at risk for infection by various species of Staphylococcus or various types of Staphylococcus aureus.Type: ApplicationFiled: April 7, 2005Publication date: October 12, 2006Applicant: Nabi BiopharmaceuticalsInventors: Ali Fattom, Jawad Sarwar, Zuzana Kossaczka, Kimberly Taylor, Sofiane Ennifar
-
Publication number: 20050136047Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: August 3, 2004Publication date: June 23, 2005Inventors: Sofiane Ennifar, Ali Fattom, Robert Naso
-
Patent number: 6773891Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 30, 2002Date of Patent: August 10, 2004Assignee: NABI BioPharmaceuticals, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20030165950Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: December 30, 2002Publication date: September 4, 2003Applicant: NABI, Inc.Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6518031Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: February 16, 2001Date of Patent: February 11, 2003Assignee: NABIInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Publication number: 20020004208Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: ApplicationFiled: February 16, 2001Publication date: January 10, 2002Inventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 6232082Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(−) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.Type: GrantFiled: December 1, 1998Date of Patent: May 15, 2001Assignee: NabiInventors: Sofiane Ennifar, Ali Ibrahim Fattom, Robert B. Naso